In this article
Johnson & Johnson
reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara.
The drug and device maker reported first-quarter revenue of $24.1 billion, up nearly 10% from a year earlier. That exceeded analysts’ estimates of $23.6 billion, according to LSEG data. Adjusted earnings came in at $2.70 per share, above the consensus estimate of $2.66.
Stelara, which topped $10 billion in annual sales at its peak, is facing biosimilar competition after losing patent protection last year. Sales of the drug fell around 60% from a year ago to $656 million.
